Balyasny Asset Management’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,648,628
| Closed | -$39.8M | – | 2511 |
|
|
2025
Q1 | $39.8M | Buy |
1,648,628
+788,179
| +92% | +$19M | 0.07% | 279 |
|
|
2024
Q4 | $34.6M | Buy |
+860,449
| New | +$34.6M | 0.05% | 338 |
|
|
2024
Q3 | – | Sell |
-185,382
| Closed | -$9.83M | – | 2386 |
|
|
2024
Q2 | $9.83M | Buy |
185,382
+76,787
| +71% | +$4.07M | 0.02% | 647 |
|
|
2024
Q1 | $8.9M | Sell |
108,595
-2,134,928
| -95% | -$175M | 0.02% | 720 |
|
|
2023
Q4 | $41.8M | Buy |
2,243,523
+121,624
| +6% | +$2.26M | 0.08% | 233 |
|
|
2023
Q3 | $23.5M | Buy |
2,121,899
+1,506,631
| +245% | +$16.7M | 0.05% | 400 |
|
|
2023
Q2 | $9.97M | Buy |
615,268
+58,661
| +11% | +$951K | 0.02% | 605 |
|
|
2023
Q1 | $9.27M | Buy |
556,607
+452,837
| +436% | +$7.54M | 0.02% | 624 |
|
|
2022
Q4 | $975K | Sell |
103,770
-2,569,794
| -96% | -$24.2M | ﹤0.01% | 1276 |
|
|
2022
Q3 | $7.27M | Buy |
2,673,564
+30,613
| +1% | +$83.3K | 0.02% | 648 |
|
|
2022
Q2 | $7.64M | Buy |
+2,642,951
| New | +$7.64M | 0.02% | 614 |
|
|
2020
Q3 | – | Sell |
-10,410
| Closed | -$75K | – | 1386 |
|
|
2020
Q2 | $75K | Buy |
+10,410
| New | +$75K | ﹤0.01% | 900 |
|
|
2019
Q4 | – | Sell |
-10,245
| Closed | -$70K | – | 1367 |
|
|
2019
Q3 | $70K | Sell |
10,245
-8,233
| -45% | -$56.3K | ﹤0.01% | 981 |
|
|
2019
Q2 | $153K | Sell |
18,478
-43,180
| -70% | -$358K | ﹤0.01% | 1274 |
|
|
2019
Q1 | $613K | Sell |
61,658
-301,948
| -83% | -$3M | ﹤0.01% | 1049 |
|
|
2018
Q4 | $2.78M | Sell |
363,606
-731,245
| -67% | -$5.59M | 0.02% | 556 |
|
|
2018
Q3 | $19.1M | Buy |
1,094,851
+839,851
| +329% | +$14.6M | 0.09% | 276 |
|
|
2018
Q2 | $2.42M | Buy |
+255,000
| New | +$2.42M | 0.01% | 720 |
|